 Breast cancer remains one of the main causes of death in women. Current endocrine treatments are aimed to target either estrogen receptors ER or to inhibit the synthesis of 17-β-estradiol E2. Emerging evidence obtained from experimental studies, as well as from human epidemiology, point to an important role for progestins in breast cancer growth. 